Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Neoadjuvant Camrelizumab/Chemo Combo Shows Clinical Activity in Locally Advanced ESCC

January 19th 2024

Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.

Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region

January 19th 2024

Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.

Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC

January 19th 2024

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers

January 18th 2024

ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.

Nivolumab/Chemo Combination Sustains Survival Improvement in Gastric/GEJ Cancers

January 18th 2024

Nivolumab plus chemotherapy improved PFS and OS vs chemotherapy alone in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, according to 4-year data from the phase 3 CheckMate 649 study.

First-Line Nivolumab Plus Chemotherapy Shows Real-World Efficacy in Gastric/GEJ/Esophageal Cancers

January 18th 2024

Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.

Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

January 18th 2024

Next-generation FGFR inhibitors show promise in early trials evaluating their efficacy and safety for the treatment of cholangiocarcinoma.

First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

January 18th 2024

Experts discuss treatment options for cholangiocarinoma and how FGFR inhibitors have changed the treatment landscape in recent years.

Dr Kim on Ongoing and Planned Research in HCC at Moffitt Cancer Center

January 17th 2024

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

Discovering Fusions Requires More Than DNA Testing in GI Cancers

January 16th 2024

E. Gabriela Chiorean, MD, highlights the importance of consistently testing for biomarkers with RNA-based tests in addition to DNA-based tests.

Dr Kim on Selecting Between Frontline Immunotherapy-Based Regimens in HCC

January 12th 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

January 12th 2024

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

January 11th 2024

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

January 11th 2024

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

January 10th 2024

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Clinical Presentations of Patients With Cholangiocarcinoma

January 10th 2024

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

Risk Factors Leading to Various Liver Cancers

January 10th 2024

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Dr In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer

January 9th 2024

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

January 9th 2024

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

NMPA Approval Sought for Frontline Cadonilimab Plus Chemo in Gastric or GEJ Adenocarcinoma

January 8th 2024

China’s NMPA has accepted the sNDA seeking the approval of cadonilimab plus chemotherapy for use in select patients with gastric or GEJ adenocarcinomas.